業(yè)執(zhí)照.jpg)
雷公藤紅素
分析標(biāo)準(zhǔn)品,HPLC≥98%
Celastrol
CAS號(hào)：34157-83-0
分子式：C29H38O4
分子量：450.61
MDL：MFCD03424073
貨號(hào) | 規(guī)格/參數(shù)/品牌 | 價(jià)格 | 貨期 |
YJ-B20707-10mg | 分析標(biāo)準(zhǔn)品,HPLC≥98% | ￥350.00 | 現(xiàn)貨 |
YJ-B20707-20mg | 分析標(biāo)準(zhǔn)品,HPLC≥98% | ￥500.00 | 現(xiàn)貨 |
YJ-B20707-200mg | 分析標(biāo)準(zhǔn)品,HPLC≥98% | ￥2300.00 | 現(xiàn)貨 |
JS27917-10mg | 98% | ￥320.00 | 現(xiàn)貨 |
JS27917-50mg | 98% | ￥850.00 | 現(xiàn)貨 |
JS27917-250mg | 98% | ￥1180.00 | 現(xiàn)貨 |
JS27917-1g | 98% | ￥2140.00 | 現(xiàn)貨 |
產(chǎn)品介紹
Tripterin (Celastrol) 是一種蛋白酶體抑制劑，有效且優(yōu)先抑制20S 蛋白酶體的胰凝乳蛋白酶樣活性，IC50 為2.5 μM。
熔點(diǎn)：185-200℃
沸點(diǎn)：645.7 ℃ at 760 mmHg
外觀：紅色粉末
溶解性：DMSO : 33.33 mg/mL (73.97 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60℃) (insoluble)
儲(chǔ)存條件：-20℃
注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。
參考文獻(xiàn)(29篇)
29. [IF=4.8] Shaohui Geng et al."Dose-dependent immunotoxic mechanisms of celastrol via modulation of the PI3K-Akt signaling pathway."Frontiers in Pharmacology.2025 May;16:
28. [IF=3.7] Jianbin Deng et al."Microneedles Constructed by Swellable Hydrogels Loaded with Celastrol for Efficient Treatment of Skin Infections Induced by Drug-Resistant Bacterial Strains."LANGMUIR.2024;XXXX(XXX):XXX-XXX
27. [IF=3.8] Xu Wang et al."A HPLC-assisted mathematical prediction method of ternary solvent systems to develop an intelligent online selection system for countercurrent chromatography solvent system."JOURNAL OF CHROMATOGRAPHY A.2024 Dec;:465585
26. [IF=3.8] Xiu-mei Luan et al."Improvement of polarity-based solvent system for countercurrent chromatography in the guidance of solvent selectivity: n-hexane/ethyl acetate/ alcohol solvents/water as an example."JOURNAL OF CHROMATOGRAPHY A.2024 Nov;1736:465389
25. [IF=13.3] Jiahang Tian et al."Mechanism of Self-Assembled Celastrol-Erianin Nanomedicine for treatment of breast cancer."CHEMICAL ENGINEERING JOURNAL.2024 Sep;:155709
24. [IF=3.3] Kang Wu et al."The anti-cancer mechanism of Celastrol by targeting JAK2/STAT3 signaling pathway in gastric and ovarian cancer."TOXICOLOGY AND APPLIED PHARMACOLOGY.2024 Aug;:117077
23. [IF=10.2] Piao Luo et al."Mechanistic engineering of celastrol liposomes induces ferroptosis and apoptosis by directly targeting VDAC2 in hepatocellular carcinoma."Asian Journal of Pharmaceutical Sciences.2023 Nov;18:100874
22. [IF=3.3] Wan Lei et al."A novel pharmaceutical preparation of Tripterygium wilfordii Hook. f. regulates macrophage polarization to alleviate inflammation in rheumatoid arthritis."JOURNAL OF PHARMACY AND PHARMACOLOGY.10.1093/jpp/rgad078
21. [IF=3] Ling Ye et al."Celastrol attenuates HFD-induced obesity and improves metabolic function independent of adiponectin signaling."ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY.
20. [IF=11.092] Hongwen Liu et al."Copper Increases the Sensitivity of Cholangiocarcinoma Cells to Tripterine by Inhibiting TMX2-Mediated Unfolded Protein Reaction Activation."Advanced Healthcare Materials.2023 Apr;:2300913
19. [IF=6.533] Liying Guo et al."Celastrol attenuates 6-hydroxydopamine-induced neurotoxicity by regulating the miR-146a/PI3K/Akt/mTOR signaling pathways in differentiated rat pheochromocytoma cells."JOURNAL OF AFFECTIVE DISORDERS.2022 Nov;316:233
18. [IF=6.656] Si-wei Wang et al."Celastrol inhibits TXNIP expression to protect pancreatic β cells in diabetic mice."PHYTOMEDICINE.2022 Sep;104:154316
17. [IF=3.981] Qian Kang et al."Application of quality by design approach to formulate and optimize tripterine loaded in nanostructured lipid carriers for transdermal delivery."J Drug Deliv Sci Tec. 2019 Aug;52:1032
16. [IF=6.4] Jinran Li et al."Celastrol Self-Stabilized Nanoparticles for Effective Treatment of Melanoma."Int J Nanomed. 2020; 15: 1205–1214
15. [IF=6.953] Yun Qian et al."Nanoparticles based on polymers modified with pH-sensitive molecular switch and low molecular weight heparin carrying Celastrol and ferrocene for breast cancer treatment."Int J Biol Macromol. 2021 Jul;183:2215
14. Sun, J, Wang, H-J, Yu, J, Li, T, Han, Y. Protective effect of celastrol on type 2 diabetes mellitus with nonalcoholic fatty liver disease in mice. Food Sci Nutr. 2020; 8: 6207– 6216. https:##doi.org/10.1002/fsn3.1917
13. Kang, Qian, et al. "Application of quality by design approach to formulate and optimize tripterine loaded in nanostructured lipid carriers for transdermal delivery." Journal of Drug Delivery Science and Technology 52 (2019): 1032-1041.https:##doi.org/10.10
12. 胡世尚,周圓圓,吳子豪,朱敏,郗雪艷,杜伯雨,喻青青.重樓皂苷Ⅶ對(duì)胰腺癌細(xì)胞的作用研究[J].湖北醫(yī)藥學(xué)院學(xué)報(bào),2020,39(06):544-550+528
11. 徐佳, 伍春蓮, 黃杰. 雷公藤紅素通過(guò)影響Akt信號(hào)通路和整合素表達(dá)抑制肺癌細(xì)胞的轉(zhuǎn)移[J]. 中國(guó)中藥雜志, 2015, 40(006):1129-1133.
10. 徐佳, 伍春蓮. 雷公藤紅素誘導(dǎo)非小細(xì)胞肺癌H1299細(xì)胞凋亡及其機(jī)制研究[J]. 中藥材, 2015, 38(09):1925-1928.
9. 柯波, 萬(wàn)才水, 李安娜,等. 雷公藤紅素誘導(dǎo)多發(fā)性骨髓瘤H929細(xì)胞凋亡[J]. 中國(guó)病理生理雜志, 2020(3):487-494.
8. 胡紹英, 張振海, 蔣艷榮, et al. 雷公藤紅素膠體二氧化硅緩釋固體分散體研究[J]. 中草藥, 2013(6):692-695.
7. 夏海建, 張振海, 賈曉斌. 雷公藤紅素緩釋滴丸的研究[J]. 中草藥, 2013, 44(7):834-838.
6. 夏海建, 2], 張振海,等. 雷公藤紅素環(huán)糊精與油自組裝小珠載藥系統(tǒng)的制備及其體外評(píng)價(jià)[J]. 中草藥, 2013, 44(019):2672-2676.
5. 吳章, 呂望, 陳新國(guó),等. 雷公藤紅素對(duì)高糖誘導(dǎo)的H9C2細(xì)胞損傷的保護(hù)作用[J]. 溫州醫(yī)科大學(xué)學(xué)報(bào), 2020(1):24-29.
4. 徐佳, 伍春蓮, 彭聰,等. 雷公藤紅素對(duì)人肺癌細(xì)胞增殖與凋亡的影響[J]. 西華師范大學(xué)學(xué)報(bào)(自然科學(xué)版), 2014(1):51-56.
3. 王黎,秦桂芳,柯鴻,魏廣民.雷公藤紅素對(duì)人急性早幼粒細(xì)胞白血病SCID小鼠移植瘤模型凝血功能的影響[J].中國(guó)中醫(yī)急癥,2019,28(02):232-235.
2. 陳小云, 張振海, 胡紹英,等. 基于硬脂酸改性納米碳酸鈣的雷公藤紅素緩釋固體分散體的研究[J]. 中國(guó)藥學(xué)雜志, 2013, 48(16):1380-1384.
1. 胡紹英, 張振海, 蔣艷榮,等. 基于HPMC-硬脂酸的雷公藤紅素緩釋固體分散體的研究[J]. 中國(guó)中藥雜志, 2012, 37(020):3052-3055.
從2011年開(kāi)始我們致力于在生命科學(xué)領(lǐng)域、生物醫(yī)學(xué)實(shí)驗(yàn)技術(shù)及論文潤(rùn)色服務(wù)，協(xié)助客戶各類實(shí)驗(yàn)服務(wù)及論文潤(rùn)色十余年，是客戶您值得信賴的科研合作伙伴!
如果您受時(shí)間、試驗(yàn)條件等限制而無(wú)法完成您的課題研究，歡迎您與我們聯(lián)系。
實(shí)驗(yàn)技術(shù)服務(wù)：
